Lafutidine, a new gastric ulcer drug of Changjiang Pharmaceutical Co., Ltd
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on the website of the State Food and Drug Administration (CFDA) on August 6, the raw materials and tablets of lafutidine, a class 3.1 chemical drug of Yichang Changjiang Pharmaceutical Co., Ltd., a joint stock company of dongyangke, will enter the site for inspection this month Lafutidine is mainly used in the treatment of gastric ulcer, duodenal ulcer and anastomotic ulcer It is the second generation histamine H2 receptor antagonist jointly developed by Fuji company and Dapeng company in Japan Compared with the first generation products cimetidine, ranitidine and famotidine, lafutidine has the advantages of high efficacy, slight side effects and low treatment cost At present, five domestic pharmaceutical companies have been approved to produce lafutidine tablets, including Kelun pharmaceutical and Cr Shuanghe Dongyangke is a large-scale professional hydrophilic foil manufacturer In recent years, the company has increased R & D investment in pharmaceutical business According to the statistics of big wisdom news agency, Guangdong dongyangguang Pharmaceutical Co., Ltd., another joint-stock subsidiary of dongyangke, has successively applied for more than 10 drugs to CFDA this year The treatment fields include respiratory tract infection, irritant dry cough, type 2 diabetes, primary Parkinson's disease, high cholesterol, tumor, influenza, unstable angina, schizophrenia, etc.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
